Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  Administered subcutaneously (s.c., under the skin) once-weekly.
• Dulaglutide — DRUG
  Administered subcutaneously (s.c., under the skin) once-weekly.

Study Details

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

Key Dates

Start date

Jan 6, 2016

Status verified

Oct 2019

Primary completion

Apr 10, 2017

Completion

May 19, 2017

Study Design

Enrollment

1,201 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Semaglutide 0.5 mg/Week
• Experimental: Semaglutide 1.0 mg/Week
• Active Comparator: Dulaglutide 0.75 mg/Week
• Active Comparator: Dulaglutide 1.5 mg/Week

Primary Outcome Measure

Change in HbA1c [ Time Frame: Week 0, week 40 ]

Locations (100)

Find similar trials in Tuscumbia, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Urinary Vitamin C Loss in Diabetic Subjects
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland